Sci Rep:膀胱癌开放染色质区域分析阐释β-catenin变异和Wnt信号与膀胱癌神经元亚型的联系

2020-11-12 AlexYang MedSci原创

膀胱尿道癌是最常见的膀胱癌,每年影响40多万人。在组织病理学上,它主要分为肌层浸润性膀胱癌(MIBC)和非肌层浸润性膀胱癌(NMIBC)。最近,主要由TCGA等联盟推动的研究揭示了MIBC和NMIBC

膀胱尿道癌是最常见的膀胱癌,每年影响40多万人。在组织病理学上,它主要分为肌层浸润性膀胱癌(MIBC)和非肌层浸润性膀胱癌(NMIBC)。最近,主要由TCGA等联盟推动的研究揭示了MIBC和NMIBC的变异情况,并确定了膀胱癌的分子亚型。由于染色质蛋白的变异率特别高,膀胱癌被认为是染色质疾病,并指出了研究表观遗传失调和这种癌症中调控的重要性。

最近,有研究人员分析了MIBC产生的ATAC-seq数据,并将他们的研究结果与基因表达和DNA甲基化数据相结合,以确定MIBC的亚组特异性调控模式。研究人员的计算分析揭示了3个MIBC调控簇,分别命名为神经元、非神经元和腔隙外群。研究人员确定神经元调控元件的靶基因参与WNT信号转导,而非神经元和腔外调控区的靶基因分别富集于上皮分化和药物代谢。神经元调控元件确定为?-catenin靶点(p=3.59e-08),包括FGF9、PROX1等参与神经发生的基因,并显著富集TCF/LEF结合位点(p=1e-584)。在三个不同的队列中,神经元调控元件调控的?-catenin靶点上调,表明了?-catenin在神经元膀胱癌中的特征。此外,与变异数据整合发现,神经元膀胱癌的致癌外显子3 ?-catenin突变显著高于非神经元膀胱癌(OR=31.33,p=1.786e-05)。

膀胱癌患者中β-catenin和 β-catenin破坏复合物组分的变异情况

最后,研究人员指出,他们的结果首次确定了神经元膀胱癌的调控元件特征,并通过β-catenin及其破坏复合物成分的变异将这些神经元调控元件与WNT信号传递联系了起来。

原始出处:

Aleyna Eray, Perihan Yağmur Güneri, Gülden Özden Yılmaz et al. Analysis of open chromatin regions in bladder cancer links β-catenin mutations and Wnt signaling with neuronal subtype of bladder cancer. Sci Rep. Oct 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1734734, encodeId=c4fd1e3473408, content=<a href='/topic/show?id=7e6818e415f' target=_blank style='color:#2F92EE;'>#Wnt信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18741, encryptionId=7e6818e415f, topicName=Wnt信号)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969033807411, createdName=jjjiang0210, createdTime=Tue Aug 24 05:32:50 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342744, encodeId=07ae1342e4472, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Nov 14 04:32:50 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575945, encodeId=708215e5945ef, content=<a href='/topic/show?id=dc0e6184243' target=_blank style='color:#2F92EE;'>#染色质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61842, encryptionId=dc0e6184243, topicName=染色质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 14 04:32:50 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598679, encodeId=4c8315986e90f, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Sat Nov 14 04:32:50 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039995, encodeId=f5cc1039995fd, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Nov 12 16:32:50 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898688, encodeId=7356898688b9, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Nov 12 13:41:41 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1734734, encodeId=c4fd1e3473408, content=<a href='/topic/show?id=7e6818e415f' target=_blank style='color:#2F92EE;'>#Wnt信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18741, encryptionId=7e6818e415f, topicName=Wnt信号)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969033807411, createdName=jjjiang0210, createdTime=Tue Aug 24 05:32:50 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342744, encodeId=07ae1342e4472, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Nov 14 04:32:50 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575945, encodeId=708215e5945ef, content=<a href='/topic/show?id=dc0e6184243' target=_blank style='color:#2F92EE;'>#染色质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61842, encryptionId=dc0e6184243, topicName=染色质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 14 04:32:50 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598679, encodeId=4c8315986e90f, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Sat Nov 14 04:32:50 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039995, encodeId=f5cc1039995fd, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Nov 12 16:32:50 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898688, encodeId=7356898688b9, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Nov 12 13:41:41 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1734734, encodeId=c4fd1e3473408, content=<a href='/topic/show?id=7e6818e415f' target=_blank style='color:#2F92EE;'>#Wnt信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18741, encryptionId=7e6818e415f, topicName=Wnt信号)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969033807411, createdName=jjjiang0210, createdTime=Tue Aug 24 05:32:50 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342744, encodeId=07ae1342e4472, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Nov 14 04:32:50 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575945, encodeId=708215e5945ef, content=<a href='/topic/show?id=dc0e6184243' target=_blank style='color:#2F92EE;'>#染色质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61842, encryptionId=dc0e6184243, topicName=染色质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 14 04:32:50 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598679, encodeId=4c8315986e90f, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Sat Nov 14 04:32:50 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039995, encodeId=f5cc1039995fd, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Nov 12 16:32:50 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898688, encodeId=7356898688b9, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Nov 12 13:41:41 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1734734, encodeId=c4fd1e3473408, content=<a href='/topic/show?id=7e6818e415f' target=_blank style='color:#2F92EE;'>#Wnt信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18741, encryptionId=7e6818e415f, topicName=Wnt信号)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969033807411, createdName=jjjiang0210, createdTime=Tue Aug 24 05:32:50 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342744, encodeId=07ae1342e4472, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Nov 14 04:32:50 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575945, encodeId=708215e5945ef, content=<a href='/topic/show?id=dc0e6184243' target=_blank style='color:#2F92EE;'>#染色质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61842, encryptionId=dc0e6184243, topicName=染色质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 14 04:32:50 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598679, encodeId=4c8315986e90f, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Sat Nov 14 04:32:50 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039995, encodeId=f5cc1039995fd, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Nov 12 16:32:50 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898688, encodeId=7356898688b9, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Nov 12 13:41:41 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
    2020-11-14 zhwj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1734734, encodeId=c4fd1e3473408, content=<a href='/topic/show?id=7e6818e415f' target=_blank style='color:#2F92EE;'>#Wnt信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18741, encryptionId=7e6818e415f, topicName=Wnt信号)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969033807411, createdName=jjjiang0210, createdTime=Tue Aug 24 05:32:50 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342744, encodeId=07ae1342e4472, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Nov 14 04:32:50 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575945, encodeId=708215e5945ef, content=<a href='/topic/show?id=dc0e6184243' target=_blank style='color:#2F92EE;'>#染色质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61842, encryptionId=dc0e6184243, topicName=染色质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 14 04:32:50 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598679, encodeId=4c8315986e90f, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Sat Nov 14 04:32:50 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039995, encodeId=f5cc1039995fd, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Nov 12 16:32:50 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898688, encodeId=7356898688b9, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Nov 12 13:41:41 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
    2020-11-12 留走人康

    膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1734734, encodeId=c4fd1e3473408, content=<a href='/topic/show?id=7e6818e415f' target=_blank style='color:#2F92EE;'>#Wnt信号#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18741, encryptionId=7e6818e415f, topicName=Wnt信号)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969033807411, createdName=jjjiang0210, createdTime=Tue Aug 24 05:32:50 CST 2021, time=2021-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342744, encodeId=07ae1342e4472, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Nov 14 04:32:50 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575945, encodeId=708215e5945ef, content=<a href='/topic/show?id=dc0e6184243' target=_blank style='color:#2F92EE;'>#染色质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61842, encryptionId=dc0e6184243, topicName=染色质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 14 04:32:50 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598679, encodeId=4c8315986e90f, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Sat Nov 14 04:32:50 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039995, encodeId=f5cc1039995fd, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Nov 12 16:32:50 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898688, encodeId=7356898688b9, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Nov 12 13:41:41 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
    2020-11-12 ms3000000449926787

    学习

    0

相关资讯

Brit J Cancer:mTORC1/2抑制剂sapanisertib 在肾癌、子宫内膜癌或膀胱癌扩张期晚期实体肿瘤的一期研究

Sapanisertib是一种口服的mTORC1/mTORC2的高选择性抑制剂。在近期发表在british journal of cancer期刊上的一项研究中,来自美国纪念斯隆-凯特琳癌症中心的科学

Eur Urol:临床再分期和肿瘤测序时肌层浸润膀胱癌新辅助化疗的不准确指标

肌层浸润性膀胱癌(MIBC)患者的标准护理包括新辅助顺铂化疗(NAC),随后进行放化疗或根治性膀胱癌切除术(RC)的巩固治疗。一些患者进行NAC后发生了剧烈的病理反应,而这些已被报道与特定基因途径的体

Sci Rep:肌肉浸润性或转移性膀胱癌患者化疗的模式和临床结果

最近,有研究人员进行了一项回顾性研究,评估了肌肉浸润性或转移性膀胱癌(MIBC/mBC)化疗治疗患者的真实世界肿瘤学结果,并将结果与RCTs和其他队列的数据进行了比较。

Cell Death & Disease:UBAC2通过BCRC-3/miRNA-182-5p/p27途径促进膀胱癌增殖

新的证据表明,泛素相关结构域蛋白2 (UBAC2)与恶性肿瘤的发生发展密切相关。然而,UBAC2在膀胱癌(BC)发展中的功能和潜在的分子机制尚未明确。

Cancer Gene Therapy:LncRNA KCNQ1OT1能够促进膀胱癌进展

长非编码RNA(lncRNA)在各种癌症中具有生物学功能的特点。LncRNA KCNQ1 反向链/反义转录1 (KCNQ1OT1)被公认能够调控各种癌症,然而其在膀胱癌中的作用仍不清楚。

CAN04联合pembrolizumab治疗多种肿瘤:I期临床研究正在进行中

制药公司Cantargia今天宣布,在美国进行的I期临床试验中,首位患者已开始使用抗体CAN04和pembrolizumab进行治疗,该试验将根据临床方案继续进行。